之江生物：2025年营收1.25亿元，同比降30.08%

Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the fiscal year 2025, primarily due to policy changes and market conditions [1] Financial Performance - The total operating revenue for 2025 was 124.91 million, a year-on-year decrease of 30.08% [1] - The net profit attributable to the parent company was -34.30 million, representing an increase in loss of 93.16 million compared to the previous year [1] - Total assets at the end of the reporting period were 376.37 million, a decrease of 0.69% from the beginning of the year [1] - The equity attributable to the parent company's owners was 334.88 million, down 7.92% from the start of the year [1] Factors Influencing Performance - The decline in revenue was mainly attributed to centralized procurement policies, tax rate adjustments, and changes in product sales structure [1] - The increase in operating losses was due to a decrease in financial income and reduced foreign exchange gains, although there was a year-on-year reduction in losses [1]